Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.ajkd.2011.02.384 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.
Kidney Int
December 2024
Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts; USA.
Apolipoprotein L1 (APOL1) variants G1 and G2 contribute to the excess risk of kidney disease in individuals of recent African ancestry. Since disease mechanisms and optimal treatments remain controversial, we study the effect of current standard-of-care drugs in mouse models of APOL1 kidney disease. Experiments were performed in APOL1 BAC-transgenic mice, which develop proteinuria and glomerulosclerosis following injection with a pCpG-free IFN-γ plasmid.
View Article and Find Full Text PDFTriptolide decreases podocytes permeability by regulating TET2-mediated hydroxymethylation of ZO-1.
Exp Biol Med (Maywood)
June 2024
Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Podocyte injury or dysfunction can lead to proteinuria and glomerulosclerosis. Zonula occludens 1 (ZO-1) is a tight junction protein which connects slit diaphragm (SD) proteins to the actin cytoskeleton. Previous studies have shown that the expression of ZO-1 is decreased in chronic kidney disease (CKD).
View Article and Find Full Text PDFIn genetic disease, an accurate expression landscape of disease genes and faithful animal models will enable precise genetic diagnoses and therapeutic discoveries, respectively. We previously discovered that variants in , encoding nitric oxide synthase 1 (NOS1) adaptor protein, cause monogenic nephrotic syndrome (NS). Here, we determined that an intergenic splice product of N / and neighboring , which precludes NOS1 binding, is the predominant isoform in mammalian kidney transcriptional and proteomic data.
View Article and Find Full Text PDFInhibition of the glucocorticoid receptor attenuates proteinuric kidney diseases in multiple species.
Nephrol Dial Transplant
June 2024
Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany.
Background: Glucocorticoids are the treatment of choice for proteinuric patients with minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS). Immunosuppressive as well as direct effects on podocytes are believed to mediate their actions. In this study, we analyzed the anti-proteinuric effects of inhibition of the glucocorticoid receptor (GR) in glomerular epithelial cells, including podocytes.
View Article and Find Full Text PDFImplications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
Kidney Int Rep
October 2023
Nephrology, Travere Therapeutics, Inc., San Diego, California, USA.
Article Synopsis
- Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease with significant treatment needs, and this study investigated how achieving complete remission (CR) of proteinuria relates to long-term kidney health.
- The analysis involved 108 patients from the DUET trial, finding that 43% achieved CR, particularly within the first year, and those with higher doses of the drug sparsentan or lower initial protein levels were more likely to achieve CR.
- Achieving CR was linked to a slower decline in kidney function, suggesting that sparsentan could provide sustained benefits in proteinuria management, indicating a positive response to treatment regardless of whether CR is maintained over time.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!